Can I read Twice-Daily Clopidogrel Vs Ticagrelor To Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention on EtoBox?

Twice-Daily Clopidogrel Vs Ticagrelor To Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention by Ranvier Fassheber is a document available to read on EtoBox.

What is Twice-Daily Clopidogrel Vs Ticagrelor To Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention about?

The TADCLOT trial compared the efficacy of ticagrelor and twice-daily clopidogrel in reducing major adverse cardiovascular events (MACEs) within the first month after primary percutaneous coronary intervention (PCI) in patients with STEMI. The study found no significant difference in MACE rates between the two treatments at one month, although ticagrelor showed a lower MACE rate in the first two weeks. Both treatments had similar bleeding rates, indicating that ticagrelor was not superior to clopidogrel in

Author

Ranvier Fassheber

Language

EN